Linda Shapiro Manning - 10 Sep 2021 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Medical Officer
Signature
/s/ Hunter Smith, attorney-in-fact for Linda Shapiro Manning
Issuer symbol
RYTM
Transactions as of
10 Sep 2021
Net transactions value
$0
Form type
4
Filing time
15 Sep 2021, 18:51:12 UTC
Next filing
11 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Award $0 +15,000 $0.000000 15,000 10 Sep 2021 Common Stock 15,000 $12.98 Direct F1
transaction RYTM Restricted Stock Units Award $0 +2,500 $0.000000 2,500 10 Sep 2021 Common Stock 2,500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were granted on September 10, 2021. 25% of the shares subject to the option will vest and become exercisable on September 10, 2022 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3 The restricted stock units vest as to 25% of the total shares on each of September 10, 2022, September 10, 2023, September 10, 2024 and September 10, 2025. The restricted stock units have no expiration date.